- Data highlights the performance benefits of HYPERVIT® Dual
Blade Vitrectomy Probe including reduced pulsatile motion and more
effective cutting
- Latest updates to NGENUITY® 3D Visualization System to be
launched at meeting and available to vitreoretinal surgeons
at the end of July
- COVID-19 resources and interactive tools offered at the
Alcon virtual booth, as well as additional retina research to be
presented
Alcon, the global leader in eye care dedicated to helping people
see brilliantly, will present key data highlighting advancements in
vitreoretinal surgery during the American Society of Retina
Specialists (ASRS) 2020 virtual annual meeting, taking place July
24-26. New data about the effectiveness of the HYPERVIT® Dual Blade
Vitrectomy Probe and other retina surgical platforms will be
presented. The company will also host a virtual exhibit booth,
complete with information on product innovations including latest
updates to the NGENUITY® 3D Visualization System (NGENUITY 1.4),
which improves and streamlines user experience.
“During our current, ever-changing health landscape, it’s
important that we continue to advance research and innovations in
vitreoretinal surgery to help provide ophthalmologists with leading
technology to safely meet the needs of patients,” said Sergio
Duplan, President, North America. “We look forward to connecting
with retina surgeons through interactive resources and activities
in our virtual booth, as well as by sharing key updates on our
innovative technologies and research, including HYPERVIT and
NGENUITY.”
HYPERVIT Dual Blade Vitrectomy Probe Provides More Stability
and Improved Performance
The HYPERVIT Dual Blade Vitrectomy Probe enhances stability and
control during microincision vitrectomy.1 New data presented at
ASRS will demonstrate how the HYPERVIT 20,000 cpm probe may provide
more continuous engagement, more effective cutting and less
repulsion of both soft and hard cataracts than single cutting 7,500
cpm probes. Additionally, another study will show HYPERVIT 20,000
cpm probes may provide more optimal vitreous aspiration near the
port than previous generation single-cutting probes, such as the
ULTRAVIT® 10,000 cpm probe.
- Poster Presentation: Dual Cutting 20,000 cpm Probe Aspiration
of Retained Lens Fragment, Presented by Dr. Martin Charles.
- Poster Presentation: Analysis of Vitreous Motion During 25+Ga
Dual Cutting 20,000 cpm Probe Aspiration, Presented by Dr. Dina
Abulon.
“During retina surgery, having a controlled workspace with
minimal movement helps drive efficiency,” said Dr. Martin Charles,
Co-director at Centro Oftalmológico Dr. Daniel Charles S.A. in
Argentina. “HYPERVIT enables me to get closer to the membrane right
above the retina with a more stable movement closer to the port and
more precise pulsatile motion. In the study we are presenting at
the meeting, the findings confirm the advanced performance of this
probe and why it’s a more efficient option for retina surgery.”
New NGENUITY 1.4 Improves Workflow in the Operating
Room
Building on the advanced technology and enhanced visualization
of the NGENUITY 3D Visualization System, Alcon will launch the
NGENUITY 1.4 upgrade at ASRS. The upgrade includes a color
optimization and a streamlined DATAFUSIONTM setup, including a
unified CONSTELLATION® workflow, allowing retina surgeons to track
key surgical parameters in real-time during surgery. These
advancements enhance the surgical cockpit, while also helping
improve patient outcomes and surgeon ergonomics during surgery. 2,3
These workflow improvements, plus the enhanced visualization,
supports surgeons in flexibility of operating room spacing and
setup when performing surgeries in the current COVID-19
environment.
Additional benefits for retina surgeons include:
- Enhancements to the CONSTELLATION system, including:
- Robustness and workflow improvements4
- Image linking and simplified mapping to image modes5
- Improved user experience with light temperature and color image
modes, minimizing the need for NGENUITY System white balance by
providing easy to access light temperature settings.6
This latest version of the NGENUITY System will be available for
the anterior segment as well later this month. Updated new features
for cataract surgeons include simultaneous viewing of the
CENTURION® Vision System surgical parameters for real-time surgical
feedback and ORA VerifEye+® cart data and aberrometer reticle
displayed on NGENUITY.
Examining Intraocular Pressure in Microincision Vitrectomy
Surgery
Key data presented at the meeting will evaluate efficacy,
stability in intraocular pressure during surgery, the number of
intra- and post-operative complications and the use of smaller
gauge instruments and surgical platforms offered by CONSTELLATION
Vision System and ACCURUS.
- Poster Presentation: A Systematic Literature Review on
Microincision Vitrectomy Surgery Tools in Controlling Intraocular
Pressure Fluctuations in Vitreoretinal Diseases, Presented by Dr.
Maria Berrocal, et al.
- Poster Presentation: A Systematic Literature Review on the
Safety and Reduction of Complications with Microincision Vitrectomy
Surgery Tools in Vitreoretinal Diseases, Presented by Dr. Caroline
Baumal, et al.
Virtual Interactive Resources and Networking
Opportunities
Visit the virtual Alcon booth to learn more about Alcon’s
corporate giving and how the company is continuing to support
communities, doctors and patients during the COVID-19 pandemic. The
virtual booth will also feature 3D product renderings and on-demand
content, including case videos and discussions from previous retina
broadcasts.
About Vitreoretinal
Surgery
Vitreoretinal surgery is a sub-specialty of ophthalmology
focused in diseases and surgery of the back of the eye including
the retina and the vitreous body of the eye. The retina is a
light-sensitive area that includes the macula, which is made-up of
light-sensitive cells that provide sharp, detailed vision. The
vitreous body of the eye is a clear gel that fills the space
between the retina and the lens. The retina, the macula, and the
vitreous body can all be subject to various diseases and conditions
that can lead to blindness or vision loss and may require the
attention of a vitreoretinal surgeon.
MIVS IMPORTANT PRODUCT
INFORMATION
The HYPERVIT® Dual Blade Vitrectomy Probe is indicated for
vitreous cutting and aspiration, membrane cutting and aspiration,
dissection of tissue and lens removal. Improper usage or assembly
could result in a potentially hazardous condition for the patient.
Mismatch of surgical components and use of settings not
specifically adjusted for a particular combination of surgical
components may affect system performance and create a patient
hazard. Do not connect surgical components to the patient’s
intravenous connections. Each surgical equipment/component
combination may require specific surgical setting adjustments.
Please refer to the User Manual for a complete list of appropriate
uses, warnings and precautions.
About NGENUITY® 3D Visualization
System
The NGENUITY® 3D Visualization System consists of a 3D
stereoscopic, high-definition digital video camera and workstation
to provide magnified stereoscopic images of objects during
micro-surgery. It acts as an adjunct to the surgical microscope
during surgery displaying real-time images or images from
recordings. Please refer to the User Manual for a complete list of
appropriate uses, warnings and precautions.
ABOUT ALCON
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning more than seven decades, we offer the
broadest portfolio of products to enhance sight and improve
people’s lives. Our Surgical and Vision Care products touch the
lives of more than 260 million people in over 140 countries each
year living with conditions like cataracts, glaucoma, retinal
diseases and refractive errors. Our more than 20,000 associates are
enhancing the quality of life through innovative products,
partnerships with eye care professionals and programs that advance
access to quality eye care. Learn more at www.alcon.com.
References
- Irannejad A, Tambat S, Abulon DJK. Retropulsion and mass flow
of 27-gauge vitrectomy probes: comparison of dual-blade/flat-tipped
probes and single-blade/beveled probes. Poster presented at: 18th
Congress of the European Society of Retina Specialists; September
20–23, 2018; Vienna, Austria.
- Eckardt, C, Paulo, EB. Heads-up surgery for vitreoretinal
procedures: an experimental and clinical study. Retina.
2016;36(1):137–47. doi:10.1097/IAE.0000000000000689.
- Yin L, Sarangapani R. Assessment of visual attributes for
NGENUITY® 3D Visualization System 1.0 for digitally assisted
vitreoretinal surgery. Alcon Modeling and Simulation. December
2017.
- Alcon data on file, November 2019.
- Alcon data on file, November 2019.
- Alcon data on file, November 2019.
Disclaimer
This press release contains
“forward-looking statements” within the meaning of the safe harbor
provisions of the United States Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be identified by
words such as: “anticipate,” “intend,” “commitment,” “look
forward,” “maintain,” “plan,” “goal,” “seek,” “believe,” “project,”
“estimate,” “expect,” “strategy,” “future,” “likely,” “may,”
“should,” “will” and similar references to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. Should one or more of these
uncertainties or risks materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those anticipated. Therefore, you should not rely on any of
these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date of its filing, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
Connect with us on Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200717005097/en/
Investor Relations Christina
Cheng + 41 589 112 110 (Geneva) + 1 817 615 2789 (Fort Worth)
investor.relations@alcon.com
Media Relations Blake Overby
+ 817 551 4328 (Fort Worth) + 1 682 321 2897 (Fort Worth)
blake-1.overby@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Sep 2023 to Sep 2024